Laboratory Co. of America Holdings (NYSE:LH) Shares Bought by HM Payson & Co.

HM Payson & Co. boosted its position in shares of Laboratory Co. of America Holdings (NYSE:LH) by 2.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,408 shares of the medical research company’s stock after acquiring an additional 55 shares during the period. HM Payson & Co.’s holdings in Laboratory Co. of America were worth $490,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Birchcreek Wealth Management LLC acquired a new position in shares of Laboratory Co. of America in the 4th quarter valued at $28,000. Ropes Wealth Advisors LLC acquired a new position in shares of Laboratory Co. of America in the 4th quarter valued at $28,000. Steward Partners Investment Advisory LLC boosted its holdings in shares of Laboratory Co. of America by 44.6% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 146 shares of the medical research company’s stock valued at $30,000 after buying an additional 45 shares in the last quarter. Childress Capital Advisors LLC acquired a new position in shares of Laboratory Co. of America in the 4th quarter valued at $32,000. Finally, Burt Wealth Advisors acquired a new position in shares of Laboratory Co. of America in the 4th quarter valued at $33,000. Institutional investors own 89.31% of the company’s stock.

Several brokerages have recently issued reports on LH. Citigroup upped their target price on shares of Laboratory Co. of America from $257.00 to $278.00 and gave the company a “buy” rating in a report on Friday, February 12th. Mizuho upped their target price on shares of Laboratory Co. of America from $242.00 to $267.00 and gave the company a “buy” rating in a report on Friday, February 12th. Jefferies Financial Group restated a “buy” rating on shares of Laboratory Co. of America in a report on Thursday, April 1st. Argus upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $245.00 price target for the company in a research report on Monday, January 11th. Finally, JPMorgan Chase & Co. upped their price target on shares of Laboratory Co. of America from $261.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 12th. Two analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Laboratory Co. of America has an average rating of “Buy” and a consensus target price of $237.87.

In other news, EVP Mark S. Schroeder sold 667 shares of the company’s stock in a transaction on Tuesday, March 30th. The shares were sold at an average price of $251.88, for a total transaction of $168,003.96. Following the transaction, the executive vice president now directly owns 5,006 shares of the company’s stock, valued at approximately $1,260,911.28. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Peter J. Wilkinson sold 2,317 shares of the company’s stock in a transaction on Thursday, February 18th. The stock was sold at an average price of $241.51, for a total transaction of $559,578.67. Following the transaction, the chief accounting officer now directly owns 710 shares in the company, valued at $171,472.10. The disclosure for this sale can be found here. Corporate insiders own 0.70% of the company’s stock.

Shares of Laboratory Co. of America stock opened at $252.30 on Thursday. The company has a market cap of $24.62 billion, a P/E ratio of 29.37, a PEG ratio of 1.15 and a beta of 1.09. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.23 and a current ratio of 1.36. Laboratory Co. of America Holdings has a one year low of $134.59 and a one year high of $259.29. The firm has a fifty day moving average of $243.70 and a two-hundred day moving average of $216.01.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Wednesday, February 10th. The medical research company reported $10.56 EPS for the quarter, topping the Zacks’ consensus estimate of $8.11 by $2.45. The company had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $3.98 billion. Laboratory Co. of America had a net margin of 6.79% and a return on equity of 21.05%. As a group, equities analysts predict that Laboratory Co. of America Holdings will post 20.84 earnings per share for the current year.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

See Also: Why are percentage gainers important?

Institutional Ownership by Quarter for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.